Swiss Atrial Fibrillation Cohort Study (SWISS-AF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02105844|
Recruitment Status : Active, not recruiting
First Posted : April 7, 2014
Last Update Posted : May 4, 2021
Swiss-AF is a prospective observational, multicentric cohort study in Switzerland. Overall, 2600 patients with documented atrial fibrillation aged >65 years will be included and followed on a yearly basis.
Yearly clinical examinations include a detailed questionnaire on personal characteristics, a resting electrocardiogram, neurocognitive function tests and questionnaires on disability and quality of life. Blood sampling and brain magnetic resonance imaging are scheduled at baseline and after 2 years of follow-up.
The main study aims of this long term prospective study are to increase our knowledge on structural brain damage and its changes over time in patients with atrial fibrillation, to gain additional insights on the incidence and underlying mechanisms of cognitive decline in patients with atrial fibrillation and to evaluate the interrelationships of structural and functional brain damage in this population.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||2415 participants|
|Official Title:||Swiss Atrial Fibrillation Cohort Study - SWISS AF|
|Actual Study Start Date :||March 2014|
|Estimated Primary Completion Date :||March 2030|
|Estimated Study Completion Date :||March 2030|
Cohort Study on patients with atrial fibrillation in Switzerland
- Stroke or systemic embolism [ Time Frame: 2018 (after an average of 2.5 years of follow-up) ]
- Hospitalization for heart failure [ Time Frame: 2018 (after an average of 2.5 years of follow-up) ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02105844
|Basel, Basel-Stadt, Switzerland, 4031|
|Study Director:||Stefan Osswald, MD, Prof.||University Hospital, Basel, Switzerland|
|Principal Investigator:||Michael Kuehne, MD, PD, exec. MBA||University Hospital, Basel, Switzerland|
|Principal Investigator:||David Conen, MD MPH||McMaster University, Population Health Research Institute, Hamilton, Canada|